MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$57,385,163
EPS
-$1.45
Unit: Dollar

Income Statement
2025-12-31
Research and development
26,879,146
General and administrative
32,221,054
Total operating expenses
59,100,200
Loss from operations
-59,100,200
Interest/investment income, net
1,395,989
Realized (loss) gain on short-term investments
-79,207
Unrealized gain on short-term investments
398,255
Total other income (expenses), net
1,715,037
Net loss
-57,385,163
Basic EPS
-1.45
Diluted EPS
-1.45
Basic Average Shares
39,479,694
Diluted Average Shares
39,479,694
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest/investment income, net$1,395,989 Unrealized gain onshort-term investments$398,255 Net loss-$57,385,163 Total other income(expenses), net$1,715,037 Realized (loss) gain onshort-term investments-$79,207 Loss from operations-$59,100,200 Total operatingexpenses$59,100,200 General andadministrative$32,221,054 Research and development$26,879,146

RELMADA THERAPEUTICS, INC. (RLMD)

RELMADA THERAPEUTICS, INC. (RLMD)